Has Niteesh Bharara, MD received payments from drug or device companies?

Yes. Drug and device makers reported $25,152 in general payments to Niteesh Bharara, MD across 265 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Niteesh Bharara, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Niteesh Bharara, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Niteesh Bharara, MD

Interventional Pain Medicine · Reston, VANPI 1144480989

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (44.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Arteriocyte Medical Systems, Inc. at 59.1% of the total. Reporting peaked in 2019 at $15,146 and has fallen 79.5% since, to $3,112 in 2025. Among interventional pain medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,152in general payments, 2019–2025

Across 265 payments — averaging $94.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Arteriocyte Medical Systems, Inc.$15K
Medtronic$3K
Abbott$3K
AbbVie$810
MML US, Inc.$697
Nevro Corp.$666
plus $2K from 32 others

What the payments were for

Consulting fees$1,5506%
Speaking & faculty fees$11,29145%
Travel & lodging$4,39817%
Food & beverage$7,91331%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Arteriocyte Medical Systems, Inc.	3	$14,855
Medtronic(2 entities)	89	$3,369
Abbott	50	$2,555
AbbVie(2 entities)	33	$810
MML US, Inc.	14	$697
Nevro Corp.	14	$666
Stimwave Technologies Incorporated	3	$296
Aesculap Implant Systems, LLC	3	$190
Boston Scientific	6	$166
4web, Inc.	1	$144
Averitas Pharma Inc.	1	$128
Bioventus LLC	2	$122
GRT US Holding, Inc.	1	$117
Vertiflex, Inc.	1	$111
Collegium Pharmaceutical, Inc.	6	$105
Saluda Medical Americas, Inc.	1	$90
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	4	$61
Amgen(2 entities)	2	$51
Curonix LLC	3	$50
Lilly USA, LLC	2	$50
Biodelivery Sciences International, Inc.	4	$48
Heron Therapeutics, Inc.	1	$48
Protega Pharmaceutials Inc	1	$47
Pfizer	2	$38
Azurity Pharmaceuticals, Inc.	2	$37
Pacira Therapeutics, Inc.	1	$33
Arbor Pharmaceuticals, Inc.	2	$32
Teva Pharmaceuticals USA, Inc.	2	$31
Stryker	2	$30
Lundbeck LLC	1	$27
Novartis	1	$23
Jazz Pharmaceuticals Inc.	1	$23
Supernus Pharmaceuticals, Inc.	1	$22
Vertex	1	$19
Sanofi-aventis U.S. LLC	1	$19
IBSA Pharma Inc.	1	$16
Biohaven Pharmaceuticals, Inc.	1	$14
Hikma Pharmaceuticals USA	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

KYPHON EXPRESS II KYPHOPAK TRAY$1,355
Proclaim Family of SCS IPGs$767
PROCLAIM$632
ReActiv8$338
Proclaim IPG$286
Senza Spinal Cord Stimulation System$283
Qutenza$245
Axium$164
Senza$155
INTELLIS$145
SPINE TRUSS SYSTEM$144
OSTEOCOOL RF ABLATION SYSTEM$141
INCEPTIV$134
Superion ISS$111
ACTIVL$105
INTELLIS ADAPTIVESTIM$102

How this compares

$25,152 in reported general payments places this provider in the 95th percentile of 52 interventional pain medicine providers in Virginia.

See all interventional pain medicine providers in Virginia →

Medicare billing

Part B allowed, 2024

$399,803

Medicare patients

321

Services billed

7,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OxycontinOxycodone Hcl	13	$4,702
MovantikNaloxegol Oxalate	11	$4,199
Pregabalin	60	$2,857
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	60	$1,955
Oxycodone Hcl	97	$1,716
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	62	$1,621
Tramadol Hcl ErTramadol Hcl	15	$1,209
Morphine Sulfate ErMorphine Sulfate	58	$1,066
Gabapentin	68	$756
Tramadol Hcl	34	$651
Tizanidine Hcl	51	$499
Diclofenac Sodium	17	$434
Methocarbamol	45	$403
Hydromorphone Hcl	17	$368
Duloxetine Hcl	24	$359

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Reston

Virgil BalintReston$894
Ketan PatelHaymarket$133K
Che TorryNewport News$48K
Sassan HassassianManassas$24K
Raj SurejaNewport News$23K
Benjamin SeemanRichmond$21K
Alok GopalWinchester$16K
Jacob LeeWinchester$14K
Yaoming GuRichmond$13K
Rae DavisLansdowne$12K

See the full list for Virginia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →